New sickle cell anemia therapy advances to Phase II clinical trials

June 12, 2013, La Jolla Institute for Allergy and Immunology

Seeking to improve the lives of sickle cell anemia sufferers around the world, researchers from the La Jolla Institute for Allergy and Immunology, the Dana-Farber/Children's Hospital Cancer Center in Boston and the BloodCenter of Wisconsin in Milwaukee and others are preparing to launch Phase II of a clinical trial to investigate a potential new therapy for reducing the disorder's severest symptoms. Sickle cell anemia is a serious, painful and chronic illness that impedes blood flow and can lead to early death. More than 100,000 Americans and several million people worldwide suffer from this genetic disorder.

The phase II trial, funded by a $10.8 million grant from the National Institutes of Health, is testing an already existing drug called Lexiscan (regadenoson - Astellas Pharma US, Inc.), which is used for diagnosing heart disease. Researchers are exploring whether the drug's anti-inflammatory effects will significantly reduce the pain and blood flow disturbances of sickle cell anemia. A Phase I safety study was completed earlier this year. Recruitment is now under way for the trial's second phase to be conducted at treatment centers in eight major U.S. cities: Boston, Baltimore, Detroit, Chicago, Cincinnati, Milwaukee, Chapel Hill, and St. Louis.

"We are excited to begin the next phase of investigating Lexiscan's potential for reducing inflammation that contributes to the poor blood flow and serious complications of sickle cell disease," says La Jolla Institute scientist Joel Linden, Ph.D., a prominent researcher whose studies laid the groundwork for the trial. "Our phase I results were promising. Participants experienced no and our tests indicated that the drug significantly reduces inflammation. It is too early to tell whether this will translate into reduced pain and tissue damage. But we remain cautiously optimistic." The Phase I results were published as the cover article in the print edition of the journal Blood on April 25th, 2013.

David G. Nathan, M.D., president emeritus of the Dana-Farber Cancer Institute, who is the trial's co-lead investigator with Dr. Linden and Joshua Field, M.D., of the BloodCenter of Wisconsin, says he is excited by the prospect of reducing some of the worst symptoms of sickle cell disease, particularly periodic disease exacerbations that lead to severe pain or breathing problems, known as vaso-occlusive crises and acute chest syndrome, respectively. Patients typically do not live beyond their late 40s or early 50s, with pulmonary problems being the most common cause of death.

"Pulmonary complications of sickle cell disease can be fatal because blood flow problems restrict the amount of oxygen going to the lungs," says Dr. Nathan, former physician-in-chief at Boston Children's Hospital and one of the world's top sickle-cell experts. "We are hopeful that the drug will reduce pulmonary injury and extend the lives of sickle cell patients."

In sickle cell anemia, the oxygen-carrying red blood cells become stiff, sticky and misshapen or "sickled" in appearance. This leads to poor blood flow that deprives tissues of oxygen and causes symptoms such as severe pain, difficulty breathing and damage to multiple organs. An inherited disorder, sickle cell anemia occurs in individuals who inherit two copies of the sickle cell gene—one from each parent. It is most common in persons of African descent, but is also found in Hispanics of Caribbean ancestry, and people of Middle Eastern, Asian, Indian, Latin American, Native American, and Mediterranean heritage.

"I treat patients with sickle cell anemia in my clinic every day," says Dr. Field. "It is a devastating disease and therapies for the two most common complications, pain and acute chest syndrome, are very limited. Lexiscan has the potential to help people with sickle cell anemia by decreasing the severity of these life-threatening problems."

The sickle cell trial grew out of research by Dr. Linden, who is a leading expert on adenosine receptors, which are known to act as a natural brake on inflammation. While Dr. Linden had previously explored adenosine's role in protecting tissues from damage due to low blood flow in single tissues such as in heart disease, he was struck one day with the idea that it might also protect people with sickle cell disease, who suffer from to most tissues.

Dr. Linden began testing his theory in mouse models about four years ago and found that adenosine-like compounds significantly reduced the damaging effects of the disease. He was aware of an existing FDA approved adenosine-like drug, Lexiscan™ that had already been approved for another use. "This was good news since it meant that Lexiscan was known to be safe in humans and could probably gain rapid approval if proven effective in clinical trials as a treatment for sickle cell disease," he said.

Dr. Linden joined forces with Dr. Nathan, who participated in the development of the only existing FDA-approved drug for sickle cell treatment, hydroxyurea, and another clinical collaborator, Dr. Field, to seek NIH funding for the Lexiscan trial. They launched the trial's first phase in 2010 using patient volunteers from Brigham and Women's Hospital in Boston and Washington University in St. Louis.

In the trial, Dr. Nathan, Dr. Field and other clinicians collected blood from patients and sent it to Dr. Linden in La Jolla for analysis of white blood cell inflammation. Gene Lin, Ph.D., a scientist in Linden's lab, has been a significant contributor to the analysis effort. The same protocol will be used in the trial's second phase.

Lexiscan is approved as a pharmacologic stress agent used for myocardial perfusion imaging (MPI), a procedure that measures coronary to help in the diagnosis of heart disease. Lexiscan is used in patients too ill to undergo exercise stress testing using a treadmill. It is given in brief (10 seconds), intravenous doses.

In Phase I of the trial, a dose escalation safety study, participants received very low doses of Lexiscan administered by continuous intravenous infusion, over 12 or 24 hours, to suppress inflammation. Following this initial study of adults with sickle cell anemia not experiencing pain crises, Phase II of the trial will expand to include patients experiencing pain crises and acute chest syndrome, and children over 14. Dr. Linden adds that Phase II will be a placebo-controlled trial.

Explore further: Sickle cell disease, sickle cell trait are not the same

Related Stories

Sickle cell disease, sickle cell trait are not the same

December 28, 2012
(HealthDay)—Both sickle cell disease and the condition known as sickle cell trait are genetic blood diseases: You're born with one or the other because of the genes inherited from your parents. Beyond that, the two conditions ...

Novel therapy helps ease pain and suffering for sickle cell patients

September 25, 2012
Chronic, debilitating pain and potential organ failure are what approximately 100,000 sickle cell patients in the United States live with each day. Yutaka Niihara, M.D., M.P.H. - lead investigator at The Los Angeles Biomedical ...

Sickle cell anemia drug safe and effective for infants and toddlers, adds treatment option

May 12, 2011
New research shows a drug commonly used to treat sickle cell anemia in adults reduces bouts of acute pain and a pneumonia-like illness, cuts hospitalization time and eases other symptoms of the disease in young patients. ...

Recommended for you

New software helps detect adaptive genetic mutations

February 20, 2018
Researchers from Brown University have developed a new method for sifting through genomic data in search of genetic variants that have helped populations adapt to their environments. The technique, dubbed SWIF(r), could be ...

New algorithm can pinpoint mutations favored by natural selection in large sections of the human genome

February 20, 2018
A team of scientists has developed an algorithm that can accurately pinpoint, in large regions of the human genome, mutations favored by natural selection. The finding provides deeper insight into how evolution works, and ...

15 new genes identified that shape human faces

February 20, 2018
Researchers from KU Leuven (Belgium) and the universities of Pittsburgh, Stanford, and Penn State have identified 15 genes that determine facial features. The findings were published in Nature Genetics.

Highly mutated protein in skin cancer plays central role in skin cell renewal

February 20, 2018
Approximately once a month, our skin completely renews itself. If this highly coordinated process goes awry, it can lead to a variety of skin diseases, ranging from skin cancer to psoriasis. Cells lining such organs as skin ...

Study of smoking and genetics illuminates complexities of blood pressure

February 15, 2018
Analyzing the genetics and smoking habits of more than half a million people has shed new light on the complexities of controlling blood pressure, according to a study led by researchers at Washington University School of ...

New mutation linked to ovarian cancer can be passed down through dad

February 15, 2018
A newly identified mutation, passed down through the X-chromosome, is linked to earlier onset of ovarian cancer in women and prostate cancer in father and sons. Kunle Odunsi, Kevin H. Eng and colleagues at Roswell Park Comprehensive ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.